Cortexyme
Marwan Sabbagh (Member of Clinical Advisory Board)
Christopher J. Senner (Independent Director)
Jeffrey L. Cummings (Member of Clinical Advisory Board)
Summary
History
Cortexyme was founded in 2012 with the goal of targeting a therapeutic approach to Alzheimer’s disease. After identifying Porphyromonas gingivalis as a potential trigger for the disease, Cortexyme’s mission evolved to develop treatments for gingipain-driven diseases, such as Alzheimer’s and Parkinson’s. Cortexyme has since advanced a lead therapeutic candidate, COR388, into Phase 2 clinical trials.
Mission
Vision
Key Team
Mark Brody (Member of Clinical Advisory Board)
Dirk Thye (CEO & Director)
June Bray (Director)
Philip S. Low (Director)
Lon S. Schneider (Member of Clinical Advisory Board)
Clive Holmes (Clinical Advisory Board Member)
Merce Boada (Member of Clinical Advisory Board)
David Munoz (Member of Clinical Advisory Board)
Mark Ryder (Member of Clinical Advisory Board)
Margaret A. McLoughlin (Independent Director)
Richard C. White (Member of Scientific Advisory Board)
Ted Yednock (Member of Scientific Advisory Board)
Ilan Zipkin (Member of Scientific Advisory Board)
Thomas P. Laughren (Clinical Advisory Board Member)
David A. Lamond (Independent Chairman of the board)
David A. Lowe (Member of Scientific Advisory Board)
Pierre N. Tariot (Member of Clinical Advisory Board)
Jan Potempa (Member of Scientific Advisory Board)
Eric M. Gordon (Member of Scientific Advisory Board)
Una S. Ryan (Lead Independent Non-Management Director)
Martin Rhys Farlow (Member of Clinical Advisory Board)
Mathew Bogyo (Member of Scientific Advisory Board)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Marwan Sabbagh (Member of Clinical Advisory Board)
Christopher J. Senner (Independent Director)
Jeffrey L. Cummings (Member of Clinical Advisory Board)